More Publications by © Chronicle Companies

n+p.PNG
Advertise with Derm.city
Chronicle Companies
Terms of Use Policy
Order "To Heal the Skin"

© Chronicle Companies 2018

Powered by Skin Chronicle International

  • Twitter - Black Circle
  • Facebook - Black Circle
  • YouTube - Black Circle
  • Home

  • Skin Chronicle

  • Primers for your Patient

  • Skin Spectrum Summit

  • Chronicle

  • Contact

  • More...

    Skin Cancer

    Seven standards for quality care of skin cancer

    October 20, 2016

    |

    by Emily Innes-Leroux, Associate Editor

     

    The National Institute of Health and Care Excellence (NICE) in the United Kingdom has released a new quality standard for skin cancer that covers the prevention, assessment, diagnosis, and management of malignant melanoma and non-melanoma (Sept. 21, 2016).

     

    The standards feature seven quality statements:

    1. Local health promotion activities

    2. GPs managing low-risk basal cell

    3. Suspected cancer pathway referrals

    4. Dermoscopy

    5. Skin cancer clinical nurse specialist

    6. Sentinel lymph node biopsy

    7. Genetic testing

    In a press release, professor Gillian Leng, deputy chief executive of NICE, said “melanoma causes more deaths than all other skin cancers combined and we don’t have reliable data for the spread of non-melanoma skin cancers. This quality standard tackles the key areas for improvement in skin cancer care . . . We want to improve the outcome for everyone diagnosed with skin cancer.”

     

    According to NICE, 29% of malignant melanomas were still being referred to secondary care via the standard GP referral in 2013, which depending on the area was between four and six weeks. The new standard states that GPs should refer people with suspected malignant melanoma for an appointment within two weeks. It recommends that GPs who remove low-risk basal cell carcinomas should maintain and audit records of their caseloads.

     

    “There are competent GPs who are trained to perform basal cell carcinoma skin surgery and may do this in GP surgeries or part of a community clinic,” said Dr. Rachael Robinson, GPSI and trust fellow in dermatology, Harrogate District Foundation Trust and member of the quality standard advisory committee. “However there is currently no agreed process in place to support good practice in this area and so this quality statement seeks to address this by recommending those GPs maintain training standards, record activity, and perform audits.”

     

    “The statement on sentinel lymph node biopsy may have a big impact,” added Dr. Robinson. “Whilst it is not available in every hospital and is not always offered to patients even where it is available, it can be a useful tool for accurately staging the melanoma, which can give more information, which may be helpful for some patients. It can enable patients’ entry into clinical trials where there are interesting developments at the moment.”

     

    Quality statement six stressed that healthcare professionals, such as members of local hospital skin cancer multidisciplinary teams or specialist skin cancer multidisciplinary teams, should discuss the advantages and disadvantages of sentinel lymph node biopsy as a staging procedure with people who have stage IB–IIC melanoma with a Breslow thickness of more than 1mm.


     


     

     

    Tags:

    NICE

    Quality standard

    Skin cancer

    melanoma

    Non-melanoma Skin Cancer

    Sentinel lymph node biopsy

    Please reload

    Featured Posts

    High-dose brachytherapy for BCC, SCC in older patients

    December 6, 2019

    Study: Makeup Products May Harbor Dangerous Bacteria

    December 4, 2019

    Newborn's immune system detects harmful skin bacteria

    December 2, 2019

    Topical rapamycin may slow skin aging

    November 29, 2019

    Statin medications may leave patients vulnerable to skin infections

    November 27, 2019

    Genes show how much sun exposure could lead to melanoma

    November 25, 2019

    Atopic eczema increases fracture risk

    November 22, 2019

    Identifying hyperhotspots in genome could be key in preventative skin cancer treatment

    November 20, 2019

    New guidelines for opioid prescribing practices for dermatologists

    November 18, 2019

    More effective rituximab dosing for pemphigus identified

    November 15, 2019

    Please reload

    Archive

    December 2019 (3)

    November 2019 (11)

    October 2019 (11)

    September 2019 (13)

    August 2019 (13)

    July 2019 (12)

    June 2019 (11)

    May 2019 (17)

    April 2019 (15)

    March 2019 (13)

    February 2019 (11)

    January 2019 (13)

    December 2018 (12)

    November 2018 (13)

    October 2018 (14)

    September 2018 (9)

    August 2018 (9)

    July 2018 (9)

    June 2018 (13)

    May 2018 (11)

    April 2018 (13)

    March 2018 (13)

    February 2018 (14)

    January 2018 (12)

    December 2017 (6)

    November 2017 (11)

    October 2017 (5)

    September 2017 (4)

    August 2017 (6)

    July 2017 (10)

    June 2017 (12)

    May 2017 (17)

    April 2017 (12)

    March 2017 (19)

    February 2017 (11)

    January 2017 (13)

    December 2016 (11)

    November 2016 (13)

    October 2016 (16)

    September 2016 (16)

    August 2016 (14)

    July 2016 (16)

    June 2016 (16)

    May 2016 (22)

    April 2016 (17)

    March 2016 (15)

    February 2016 (12)

    January 2016 (11)

    December 2015 (13)

    November 2015 (19)

    October 2015 (13)

    September 2015 (15)

    July 2015 (3)

    June 2015 (22)

    March 2015 (3)

    Please reload

    Follow Us
    • Grey Facebook Icon
    • Grey YouTube Icon
    • Grey Instagram Icon
    • Grey Twitter Icon